| Bind-X–High-Tech Gründerfonds: investment, 202308 existing investor HTGF |
2023-08-01 |
| Bind-X–K&K 1: investment, 202308 financing round Series B totalling €10m incl new investor K&K 1 |
2023-08-01 |
| Bind-X–Saxovent: investment, 202308 financing round Series B totalling €10m incl new investor Saxovent Smart Eco Investments |
2023-08-01 |
| Bind-X–SEVERAL: investment, 202308 financing round Series B €10m with HG Ventures + K&K1 + Greeneering Invest + Saxovent |
2023-08-01 |
| Bind-X–Vantage Value: investment, 202308 existing investor Vantage Value |
2023-08-01 |
| Cellbox Solutions–EU (govt): grant, 202308–202507 EIC Accelerator grant €2.5m |
2023-08-01 |
| Reata–Biogen: investment, 202307– acquisition $7.3b in cash by Biogen at $172.5/share ANNOUNCED |
2023-07-28 |
| AaviGen–Hopp Group: investment, 202307 financing round Series B €17m from existing investor DH-LT Investments GmbH |
2023-07-26 |
| Crescendo Biologics–BioNTech: investment, 202307 financing round totalling $32m incl existing investor BioNTech |
2023-07-24 |
| Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors |
2023-07-24 |
| Epigenomics–New Day Diagnostics: investment, 202307– acquisition of substantially all assets up to $12.05m plus license + milestones by New Day SIGNED |
2023-07-24 |
| Immatics–BMS: investment, 202307 private placement $35m with 2.42m ordinary shares at $14.461/share |
2023-07-24 |
| Roche–Alnylam: zilebesiran, 202307– collab $310m upfront + milestones developm + commerc in US w cost/profit sharing + excl ww outside US by Roche |
2023-07-24 |
| LimmaTech Biologics–Trophic Communications: public relations, 202307 service existent by Trophic |
2023-07-20 |
| Mage Biologics–SEVERAL: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| Mage Biologics–TVM: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| Mage Biologics–Zeria: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| TVM–MC Services: public relations, 202307 service existent by MC Services |
2023-07-20 |
| Pieris–Stifel: financial services, 202307– supply service Pieris retains Stifel Nicolaus as excl financial advisor to evaluate strategic options |
2023-07-18 |
| AATec Medical–SEVERAL: investment, 202307 seed financing round €2.7m from private investors + industry experts + family offices |
2023-07-17 |
| DTx Pharma–Novartis: investment, 202307 acquisition of DTx Pharma for $500m upfront + $500m milestones |
2023-07-17 |
| Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital |
2023-07-12 |
| Vertama–BACB: investment, 202307 seed financing round totalling 7-digit € incl investor Berlin Angel Fund |
2023-07-12 |
| Vertama–High-Tech Gründerfonds: investment, 202307 seed financing round totalling 7-digit € incl lead investor HTGF |
2023-07-12 |
| Vertama–OTHER: investment, 202307 seed financing round totalling 7-digit € incl renowned business angels |
2023-07-12 |
| Vertama–SEVERAL: investment, 202307 seed financing round 7-digit € led by HTGF |
2023-07-12 |
| Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries |
2023-07-11 |
| Celares–Biosynth: investment, 202307 acquisition of Celares by Biosynth |
2023-07-11 |
| Mallia Therapeutics–MC Services: public relations, 202307 service existent by MC Services |
2023-07-11 |
| Mallia Therapeutics–SEVERAL: investment, 202307c– seed financing round raising ongoing 7/23 |
2023-07-11 |
| BioNTech–Doer Biologics: biopharmaceuticals, 202308– license ww to use Doer Bio discovery to develop + market biotherapeutics against one target |
2023-07-10 |
| TolerogenixX–Akampion: public relations, 202307 service existent by Akampion |
2023-07-06 |
| TolerogenixX–Bruchmann Group: investment, 202307 financing round Series A 2nd closing totalling €7m incl new investor DB Speciality |
2023-07-06 |
| TolerogenixX–SEVERAL: investment, 202307 financing round Series A 2nd closing €7m bringing total round to €11.6m |
2023-07-06 |
| Zoetis–Numaferm: peptide technology, 202307– license + collab €na using peptein technology for RnD of veterinary therapeutics |
2023-07-06 |
| Acousia Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| Cellbox Solutions–Akampion: public relations, 202307 service existent by Akampion |
2023-07-05 |
| inContAlert–SEVERAL: investment, 202307 pre-seed financing round €1.5m led by HTGF + Bayern Kapital + Carma Fund |
2023-07-01 |
| Emergence Therapeutics–Lilly: investment, 202306 acquisition 100% of Emergence Therapeutics AG by Eli Lilly |
2023-06-29 |
| Gleamer–Heal Capital: investment, 202306 financing round Series B totalling €27m incl new + co-lead investor Heal Capital |
2023-06-28 |
| Gleamer–SEVERAL: investment, 202306 financing round Series B €27m led by Supernova Invest + co-led by Heal Capital |
2023-06-28 |
| MoonLake–Consilium: public relations, 202306 service existent by Consilium Strategic Communications |
2023-06-28 |
| Astraveus–Merck (DE): investment, 202306 seed financing round totalling €16.5m incl co-investor M Ventures |
2023-06-27 |
| Astraveus–SEVERAL: investment, 202306 seed financing round €16.5m led by AdBio Partners |
2023-06-27 |
| Docflix–SEVERAL: investment, 202306 seed financing round €2m led by HTGF + Brandenburg Kapital |
2023-06-27 |
| EBAMed–EFI Lake Geneva Ventures: investment, 202306 financing round Series A totalling €14.35m incl co-investor Efficient Frontier Investing |
2023-06-27 |
| EBAMed–EU (govt): investment, 202306 financing round Series A totalling €14.35m incl co-investor EIC Fund |
2023-06-27 |
| EBAMed–LIFIT Venture Capital Italia: investment, 202306 financing round Series A totalling €14.35m incl co-investor LIFIT |
2023-06-27 |
| EBAMed–Mayo Clinic: investment, 202306 financing round Series A totalling €14.35m incl existing + co-investor Mayo Clinic |
2023-06-27 |
| EBAMed–Occident: investment, 202306 financing round Series A totalling €14.35m incl co-investor Occident |
2023-06-27 |
| EBAMed–Panakès Partners: investment, 202306 financing round Series A totalling €14.35m incl lead investor Panakès Partners |
2023-06-27 |
| EBAMed–SEVERAL: investment, 202306 financing round Series A €14.35m led by Panakès Partners |
2023-06-27 |
| Hema.to–SEVERAL: investment, 202306 seed financing round €3.6m with Elaia Partners + Heal Capital + HTGF |
2023-06-26 |
| MoonLake–SEVERAL: investment, 202306 public offering $400m+$60m with 8m+1.2m Class A ordinary shares at $50/share |
2023-06-26 |
| Lunaphore–Bio-Techne: investment, 202306– acquisition by of Lunaphore by Bio-Techne ANNOUNCED |
2023-06-22 |
| MESI–SHS Capital: investment, 202306 investment €18m by SHS in MESI |
2023-06-22 |
| Sanofi–SandboxAQ: AI-based drug discovery, 202306 collab existent disclosed of Sanofi with AQBioSim |
2023-06-22 |
| Tagworks Pharmaceuticals–Novartis: investment, 202306 financing round Series A totalling $65m incl co-investor Novartis Venture Fund |
2023-06-22 |
| Tagworks Pharmaceuticals–SEVERAL: investment, 202306 financing round Series A $65m led by Ysios Capital + Gilde Healthcare |
2023-06-22 |
| Pieris–Kendall Investor Relations: public relations, 202306 supply service existent IR by Kendall IR |
2023-06-21 |
| Innovative Health Initiative–EU (govt): grant, 202306– funding €24m for IMAGIO project from IHI |
2023-06-20 |
| Innovative Health Initiative–Philips: targeted cancer therapy, 202306– Philips is coordinating partner ot the IMAGIO project of IHI |
2023-06-20 |
| Innovative Health Initiative–Thermosome: targeted cancer therapy, 202306– Thermosome is partner in IMAGIO project of IHI |
2023-06-20 |
| Thermosome–Innovative Health Initiative: grant, 202306– funding €1.3m as partner in IMAGIO project of IHI |
2023-06-20 |
| DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF |
2023-06-14 |
| Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen |
2023-06-13 |
| Dynamic42–OTHER: investment, 202306 financing round Series A totalling mid-7-figure € incl a family office from the health sector |
2023-06-13 |
| Dynamic42–SEVERAL: investment, 202306 financing round Series A mid-7-figure € incl investors bm-t + a familly office |
2023-06-13 |
| Dynamic42–Thuringia (govt): investment, 202306 financing round Series A totalling mid-7-figure € incl existing investor bm-t |
2023-06-13 |
| Chinook Therapeutics–Novartis: investment, 202306– acquisition $3.2b cash upfront + $300m cash milestones of Chinook by Novartis ANNOUNCED |
2023-06-12 |
| Upstream Bio–SEVERAL: investment, 202306 financing round Series B $200m co-led by Enavate Sciences + Venrock Healthcare Capital Partners |
2023-06-08 |
| OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science |
2023-06-07 |
| Bayer–Acuitas Therapeutics: LNP technology, 202306– collab €na using LNP technology to deliver RNA payloads to liver |
2023-06-05 |
| ITM–SEVERAL: investment, 202306 financing round €255m led by Temasek |
2023-06-05 |
| Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform |
2023-06-05 |
| 4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
| Bico–Swiss Life: real estate, 202306– leaseback 15y of property in Berlin by Scienion from BEOS Light Industrial Germany I fund |
2023-06-01 |
| Swiss Life–Bico: real estate, 202306 acquisition €21m of new Scienion property in Berlin by BEOS Light Industrial Germany I fund |
2023-06-01 |
| Synaffix–Lonza: investment, 202306 acquisition €100m upfront cash + €60m milestones of Synaffix by Lonza |
2023-06-01 |
| Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones |
2023-06-01 |
| Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau |
2023-05-29 |
| CARTemis Therapeutics–Germany (govt): grant, 202305– BMBF grant €4.6m to develop CAR T-cell therapy targeting CXCR5 (to MDC+Charité) |
2023-05-26 |
| Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group |
2023-05-25 |
| Prosion–10xDNA: investment, 202205 existent 7-figure seed investment by 10xDNA |
2023-05-23 |
| Smartbax–Boehringer: investment, 202305 seed financing round totalling €1.2m incl existing investor BIVF |
2023-05-23 |
| Smartbax–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €1.2m incl new investor HTGF |
2023-05-23 |
| Smartbax–SEVERAL: investment, 202305 seed financing round €1.2m from BIVF + HTGF |
2023-05-23 |
| Smartbax–Trophic Communications: public relations, 202305 service existent by Trophic |
2023-05-23 |
| Oncimmune–Freenome: investment, 202305 acquisition of Oncimmune Ltd by Freenome |
2023-05-22 |
| VectivBio–Ironwood: investment, 202305–202306 acquisition $1b net of cash/debt cash tender offer at $17/share |
2023-05-21 |
| Traceless Materials–Germany (govt): grant, 202305– BMUV funding €5.1m for construction of demonstration plant |
2023-05-19 |
| Boundless Bio–Bayer: investment, 202305 financing round Series C totalling $100m incl new + co-lead investor Leaps by Bayer |
2023-05-16 |
| Boundless Bio–Nextech: investment, 202305 financing round Series C totalling $100m incl existing + co-investor Nextech Invest |
2023-05-16 |
| Boundless Bio–SEVERAL: investment, 202305 financing round Series C $100m co-led by Leaps by Bayer + RA Capital |
2023-05-16 |
| Boundless Bio–Sophia Genetics: molecular diagnostics, 202305 existent collab develpm ecDNA Harboring Oncogenes clinical trial assay ECHO for BBI-355 |
2023-05-16 |
| Dualyx–High-Tech Gründerfonds: investment, 202305 financing round Series A totalling €40m incl existing + co-investor HTGF |
2023-05-15 |
| Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners |
2023-05-15 |
| Exazyme–AIX Ventures: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
| Exazyme–Altantic Labs: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
| Exazyme–SEVERAL: investment, 202305 seed financing round €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
